Adial Pharmaceuticals, Inc. (ADIL) — SEC Filings
Adial Pharmaceuticals, Inc. (ADIL) — 46 SEC filings. Latest: 8-K (Apr 9, 2026). Includes 31 8-K, 6 10-Q, 2 DEF 14A.
View Adial Pharmaceuticals, Inc. on SEC EDGAR
Overview
Adial Pharmaceuticals, Inc. (ADIL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 9, 2026: ADIAL PHARMACEUTICALS, INC. filed an 8-K on April 9, 2026, reporting changes in officers and compensatory arrangements. Specifically, the company entered into a Form of Restricted Stock Award Agreement under its 2017 Equity Incentive Plan.
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 5 bearish, 39 neutral, 2 mixed. The dominant filing sentiment for Adial Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Adial Pharmaceuticals, Inc. (ADIL) has filed 31 8-K, 6 10-Q, 1 S-1/A, 2 DEF 14A, 2 S-1, 2 10-K, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of ADIL's 40 recent filings, 7 were flagged as high-risk, 20 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$5,981,008 |
| EPS | -$0.45 |
| Cash Position | $4,606,289 |
| Total Assets | $5,659,847 |
| Total Debt | $1,154,756 |
Key Executives
- Dr. William J. R. Dean
- Cary Claiborne
- Leslie Marlow, Esq.
- Patrick J. Egan, Esq.
- Ron Ben-Bassat, Esq.
- Eric Victorson, Esq.
- Dr. Robert L. Smith
- Ms. Jennifer L. Jones
- Mr. David K. Lee
- Ms. Karen L. Smith
Industry Context
The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Adial Pharmaceuticals operate in a competitive landscape where innovation and successful clinical trials are paramount. The sector is also subject to evolving reimbursement policies and market access challenges, impacting revenue generation and profitability.
Top Tags
8-K (6) · pharmaceuticals (6) · filing (5) · executive-appointment (5) · equity-sale (4) · Pharmaceuticals (4) · 10-Q (4) · material-definitive-agreement (3) · Biotechnology (3) · Clinical Trials (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $1.79M | Decreased from $2.19M in Q3 2024, indicating a narrowing of losses. |
| Net Loss (9 months 2025) | $5.98M | Significantly lower than $11.13M in 9 months 2024, primarily due to absence of inducement expense. |
| Cash and Cash Equivalents | $4.61M | Increased from $3.75M at Dec 31, 2024, but still insufficient for 12 months of operations. |
| Net Cash from Financing | $5.87M | Raised through stock sales and warrant exercises, crucial for current liquidity. |
| Common Shares Outstanding | 23.84M | Increased from 6.47M at Dec 31, 2024, indicating significant shareholder dilution. |
| R&D Expenses (9 months 2025) | $2.00M | Decreased by 19.9% from $2.50M in 9 months 2024. |
| Accumulated Deficit | $87.98M | Increased from $81.99M at Dec 31, 2024, reflecting ongoing losses. |
| Loss per share (Q3 2025) | $0.08 | Improved from $0.38 in Q3 2024, partly due to increased share count. |
| Net Loss (Q2 2025) | $1.96M | Reduced from $2.46M in Q2 2024, showing improved financial performance. |
| Net Loss (H1 2025) | $4.19M | Significantly lower than $8.93M in H1 2024, primarily due to absence of inducement expense. |
| Net Proceeds from Financing | $5.3M | Received in May and June 2025 from warrant exercises and equity issuances, boosting cash reserves. |
| Loss per share (H1 2025) | $0.49 | Improved from $2.50 in H1 2024, despite increased share count. |
| Research and Development Expenses (Q2 2025) | $732K | Decreased from $1.01M in Q2 2024, reflecting potentially lower development activity or efficiency. |
| Commission File Number | 001-38323 | Identifies the company's SEC filing history. |
| Registration No. | 333-287826 | SEC registration number for the S-1 filing |
Frequently Asked Questions
What are the latest SEC filings for Adial Pharmaceuticals, Inc. (ADIL)?
Adial Pharmaceuticals, Inc. has 46 recent SEC filings from Jan 2024 to Apr 2026, including 31 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ADIL filings?
Across 46 filings, the sentiment breakdown is: 5 bearish, 39 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Adial Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Adial Pharmaceuticals, Inc. (ADIL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Adial Pharmaceuticals, Inc.?
Key financial highlights from Adial Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ADIL?
The investment thesis for ADIL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Adial Pharmaceuticals, Inc.?
Key executives identified across Adial Pharmaceuticals, Inc.'s filings include Dr. William J. R. Dean, Cary Claiborne, Leslie Marlow, Esq., Patrick J. Egan, Esq., Ron Ben-Bassat, Esq. and 5 others.
What are the main risk factors for Adial Pharmaceuticals, Inc. stock?
Of ADIL's 40 assessed filings, 7 were flagged high-risk, 20 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Adial Pharmaceuticals, Inc.?
Forward guidance and predictions for Adial Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.